How big is Avidity Biosciences, Inc.?

As of Jun 18, Avidity Biosciences, Inc. has a market capitalization of $3.54 billion, with recent net sales of $8.92 million and a net profit of -$369.22 million. The company reported shareholder's funds of $1.42 billion and total assets of $1.56 billion as of Dec 24.

Market Cap: As of Jun 18, Avidity Biosciences, Inc. has a market capitalization of 3,539.01 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Avidity Biosciences, Inc. reported net sales of 8.92 million and a net profit of -369.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,424.96 million and total assets of 1,563.89 million.

What does Avidity Biosciences, Inc. do?

Avidity Biosciences, Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOC) for serious diseases, with a market cap of approximately $3.54 billion. As of March 2025, it reported net sales of $2 million and a net loss of $116 million.

Overview: <BR>Avidity Biosciences, Inc. is a biopharmaceutical company focused on developing oligonucleotide-based therapies known as Antibody Oligonucleotide Conjugates (AOC) to treat serious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -116 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,539.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -27.79% <BR>Price to Book: 2.66<BR><BR>Contact Details: <BR>Address: 10975 N. TORREY PINES RD., #150, LA JOLLA CA : 92037 <BR>Tel: 1 858 4017900 <BR>Website: http://www.aviditybiosciences.com/

Should I buy, sell or hold Avidity Biosciences, Inc.?

Who are in the management team of Avidity Biosciences, Inc.?

As of March 2022, Avidity Biosciences, Inc.'s management team includes Dr. Troy Wilson (Executive Chairman), Ms. Sarah Boyce (President and CEO), and several directors, including Ms. Jean Kim, Ms. Tamar Thompson, and independent directors Dr. Noreen Henig, Dr. Edward Kaye, and Mr. Carsten Boess. The team features a blend of executive leadership and independent oversight.

As of March 2022, the management team of Avidity Biosciences, Inc. includes the following individuals:<BR><BR>- Dr. Troy Wilson, who serves as the Executive Chairman of the Board and is a Co-Founder.<BR>- Ms. Sarah Boyce, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Jean Kim, who is a Director.<BR>- Ms. Tamar Thompson, who is a Director.<BR>- Mr. Carsten Boess, who is an Independent Director.<BR>- Dr. Noreen Henig, who is an Independent Director.<BR>- Dr. Edward Kaye, who is also an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, highlighting a diverse governance structure.

Is Avidity Biosciences, Inc. technically bullish or bearish?

As of September 26, 2025, Avidity Biosciences, Inc. shows a bullish technical trend with strong momentum indicators, despite mixed signals from the KST and recent underperformance compared to the S&P 500.

As of 26 September 2025, the technical trend for Avidity Biosciences, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish weekly and mildly bullish monthly. However, the KST shows a mixed signal with weekly bullishness and monthly mildly bearishness, while the Dow Theory indicates no trend weekly but mildly bullish monthly. The stock has outperformed the S&P 500 on a year-to-date basis with a return of 47.70% compared to 12.96%, but has underperformed over the last month and year. Overall, the current technical stance is bullish with strong momentum indicators supporting this view.